Roles of Gut Microbiota and Metabolites in Pathogenesis of Functional Constipation

• Published in: Evidence-based complementary and alternative medicine Vol. 2021; pp. 1 - 12
• Main Authors: Wang, Jun-Ke, Yao, Shu-Kun
• Format: Journal Article
• Language: English
• Published: New York Hindawi 2021; John Wiley & Sons, Inc
• Subjects: Constipation; Defecation; Enteric nervous system; Epithelial cells; Fatty acids; Feces; Fermentation; Gastric motility; Glucagon; Glucagon-like peptide 1; Gut microbiota; Gut-brain axis; Intestinal microflora; Irritable bowel syndrome; Metabolism; Metabolites; Microbiomes; Microbiota; Motility; Nervous system; Pathogenesis; Pathophysiology; Pelvis; Polyamines; Probiotics; Review; Salts; Smooth muscle; Species richness; Therapeutic targets
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2021/5560310

Functional constipation (FC), a condition characterized by heterogeneous symptoms (infrequent bowel movements, hard stools, excessive straining, or a sense of incomplete evacuation), is prevalent over the world. It is a multifactorial disorder and can be categorized into four subgroups according to different pathological mechanisms: normal transit constipation (NTC), slow transit constipation (STC), defecatory disorders (DD), and mixed type. Recently, growing evidence from human and animals has pointed that there was a strong association between gut microbiota and FC based on the brain-gut-microbiome axis. Studies have reported that the main characteristics of gut microbiota in FC patients were the relative decrease of beneficial bacteria such as Lactobacillus and Bifidobacterium, the relative increase of potential pathogens, and the reduced species richness. Gut microbiota can modulate gut functions through the metabolites of bacterial fermentation, among which short-chain fatty acids (SCFAs), secondary bile salts (BAs), and methane occupied more important positions and could trigger the release of gut hormones from enteroendocrine cells (EECs), such as 5-hydroxytryptamine (5-HT), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). Subsequently, these gut hormones can influence gut sensation, secretion, and motility, primarily through activating specific receptors distributed on smooth muscle cells, enteric neurons, and epithelial cells. However, research findings were inconsistent and even conflicting, which may be partially due to various confounding factors. Future studies should take the associated confounders into consideration and adopt multiomics research strategies to obtain more complete conclusions and to provide reliable theoretical support for exploring new therapeutic targets.